KENICHI AKAMATSU

CEO, President
Megakaryon Corporation

Kenichi Akamatsu joined Chugai Pharmaceutical Co., Ltd. in 1980, where he worked on anticancer drugs, hematopoietic factors (EPO, G-CSF) and antibody drugs (Actemra) in the Research Department. Since 2001, he has held various positions, including Deputy Director of the CMC Planning and Promotion Department, Director of the CMC Regulatory Affairs Department, and Director of the Biotechnology Research Institute.

He joined Megakaryon Corporation in 2013 as a director and chief operating officer, and was appointed president in 2019. In 2022, he led the first-in-human clinical trial of allogeneic human iPSC-derived HLA homozygous platelets. He is currently working on the practical application of allogeneic human iPSC-derived HLA-null “universal” platelets.

Ph. D. in Pharmacology.